好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Utilizing Holistic strategies for improvement of quality of life of patients with Generalized Myasthenia Gravis.
General Neurology
General Neurology Posters (7:00 AM-5:00 PM)
054

To describe our experience with utilizing holistic strategies for improvement of quality of life of patients with Myasthenia Gravis. 


Although established pharmacological therapies for Myasthenia Gravis are effective in managing disease symptoms, these therapies do not address the physical, emotional, financial and social factors associated with the disease. Such factors significantly affect the overall quality of life of patients. In this study, we provided holistic care to 15 patients with generalized myasthenia gravis and addressed their; 1. Physical Wellness with balanced diet and aerobic exercise strategies, 2. Emotional Wellness with relaxation strategies and breathing techniques, 3. Social Wellness with enrollment in MG support groups, 4. Financial Well being with resources for financial and disability assistance. 


Retrospective chart review of 15 patients with myasthenia gravis treated with holistic strategies to address physical, emotional, financial and social wellness for 12 months. Outcome measures were Myasthenia Gravis–Quality of Life (MG-QOL) scores. Data collected at 3-monthly intervals for 12 months before and after initiation of holistic approach were analyzed.


7 patients were male and 8 were females with mean age of 52.8 years with standard deviation of 18.65 years. 4 patients were MGFA class 2A, 4 were MGFA Class 2B, 6 were MGFA class 3A, 1 patient was MGFA class 3B. 13 patients were Caucasian and 2 patients were African American. 13 patients were Acetylcholine receptor Antibody (AChR) positive, 2 were AChR negative. In the 12 months before initiation of holistic strategies, MG-QOL scores were relatively stable. After its initiation, clinically meaningful reductions (≥2 points) in total MG-QOL scores were observed 3 months after and were maintained to month 12 in all patients.


Our study demonstrated clinically significant reduction in outcome measures of MG-QOL score, indicating improved quality of life with introduction of holistic strategies in patients with MG. 


Authors/Disclosures
Nakul Katyal, MD (University of Kentucky)
PRESENTER
Dr. Katyal has nothing to disclose.
Nakul Katyal, MD (University of Kentucky) Dr. Katyal has nothing to disclose.
Raghav Govindarajan, MD, FAAN (HSHS St. Elizabeth Medical Group) Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MT pharma. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MT pharma . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Catalyst. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biohaven. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Takeda. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Govindarajan has received research support from Band of Hope . The institution of Dr. Govindarajan has received research support from Alexion. Dr. Govindarajan has received publishing royalties from a publication relating to health care.